NCT03736616View on ClinicalTrials.gov

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

PHASE2UnknownINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

August 16, 2019

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

Carboplatin

Chemotherapy

DRUG

Ifosfamide

Chemotherapy

DRUG

Etoposide

Chemotherapy

BIOLOGICAL

Rituximab

Anti-CD20 mAb

DRUG

Carmustine

Chemotherapy

DRUG

Cytarabine

Chemotherapy

DRUG

Melphalan

Chemotherapy

OTHER

Autologous HSCT

Cellular Therapy

DRUG

Acalabrutinib

Bruton's Tyrosine Kinase Inhibitor

Trial Locations (1)

98104

RECRUITING

Swedish Cancer Institute, Seattle

Sponsors

Collaborators (1)

Acerta Pharma BV

All Listed Sponsors

collaborator

Acerta Pharma BV

INDUSTRY

lead

Swedish Medical Center

OTHER